Papers on
mgl-1
Novel genetic causes for cerebral visual impairment.de Vries et al., Nijmegen, Netherlands. In Eur J Hum Genet, Oct 2015
In addition, in 11 patients (44%) with CVI, variants in one or more candidate genes were identified (ACP6, AMOT, ARHGEF10L, ATP6V1A, DCAF6, DLG4, GABRB2, GRIN1, GRIN2B, KCNQ3, KCTD19, RERE, SLC1A1, SLC25A16, SLC35A2, SOX5, UFSP2, UHMK1, ZFP30).
Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach.Fortune et al., Baltimore, United States. In Expert Opin Drug Discov, 2013
EXPERT OPINION: In the genetically informed network, known genes and identified key connecting components, including DLG4 (a developmental gene), PSD-95 (a synaptic scaffolding protein) and PSEN1 (presenilin, a regulator of secretase), conform a group of potential pharmacological targets.
Research progress on neurobiology of neuronal nitric oxide synthase.Zhu et al., Nanjing, China. In Neurosci Bull, 2011
There are primarily 9 nNOS-interacting proteins, including post-synaptic density protein 95 (PSD95), clathrin assembly lymphoid leukemia (CALM), calcium/calmodulin-dependent protein kinase II alpha (CAMKIIA), Disks large homolog 4 (DLG4), DLG2, 6-phosphofructokinase, muscle type (PFK-M), carboxy-terminal PDZ ligand of nNOS (CAPON) protein, syntrophin and dynein light chain (LC).